Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Hoth Therapeutics Inc (HOTH)

Hoth Therapeutics Inc (HOTH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 52,113
  • Shares Outstanding, K 10,119
  • Annual Sales, $ 0 K
  • Annual Income, $ -2,500 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 11.77

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.61 +11.83%
on 01/14/20
7.25 -28.97%
on 12/30/19
-0.26 (-4.81%)
since 12/20/19
3-Month
3.26 +57.98%
on 10/31/19
7.25 -28.97%
on 12/30/19
+0.83 (+19.24%)
since 10/21/19

Most Recent Stories

More News
Hoth Completes Animal Safety Study of Proprietary BioLexa Platform for the Treatment of Atopic Dermatitis

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing new generation therapies for dermatological and immunological disorders such as atopic dermatitis, psoriasis, asthma...

HOTH : 5.15 (+2.71%)
Emerging Markets Report: A Very Big Deal

It doesn't take an analyst to suggest that high value merger and acquisition activity in any industry is a bullish sign. And it assuredly doesn't take any research firm at all to suggest that an eczema...

LLY : 140.91 (+0.95%)
HOTH : 5.15 (+2.71%)
Hoth Therapeutics Exercises Patent Licensing Option with the George Washington University to Further Develop a Therapeutic for Cancer Patients Suffering Cutaneous Changes Like Rash and Hair Loss, as Well as Other Neurogenic Inflammation Side Effects

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis, psoriasis...

HOTH : 5.15 (+2.71%)
Hoth Therapeutics Exercises Patent Licensing Option with the George Washington University to Further Develop a Therapeutic for Cancer Patients Suffering Cutaneous Changes Like Rash and Hair Loss, as Well as Other Neurogenic Inflammation Side Effects

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis, psoriasis...

HOTH : 5.15 (+2.71%)
Emerging Markets Report: Acne, Eczema, and Asthma

The headline of our written offering today probably appears a little different from our regular titles. Typically we don't lead with things that are so widely despised or feared. But when we are discussing...

HOTH : 5.15 (+2.71%)
Hoth Therapeutics, Inc. Issues 2019 Shareholder Letter

Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological and immunological disorders such as atopic...

HOTH : 5.15 (+2.71%)
Emerging Markets Report: A Pretty Good Month

As the holidays roll into November and December many companies go quietly into the New Year, eschewing news releases or large scale investor communication. That has definitely not been the case for Hoth...

HOTH : 5.15 (+2.71%)
Hoth Therapeutics Enters into Research Collaboration Agreement with Weill Cornell Medicine to Examine the Efficacy of RAMBA in Blocking Acne Pathogenic Gene Expression

Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic...

HOTH : 5.15 (+2.71%)
Hoth Therapeutics Announces the Appointment of Dr. William Weglicki, M.D. to Scientific Advisory Board

Hoth Therapeutics, Inc. (NASDAQ: HOTH), ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic...

HOTH : 5.15 (+2.71%)
Emerging Markets Report - Hoth Therapeutics on the Fast Track Toward Delivering Eczema Therapy Products to Market

Nearly every person suffering from atopic dermatitis, more popularly known as "eczema," knows just how difficult it can be to find effective remedies for his or her condition. Many prescription and over-the-counter...

HOTH : 5.15 (+2.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade HOTH with:

Business Summary

Hoth Therapeutics Inc. is a development stage biopharmaceutical company. It focused on therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. The company's BioLexa(TM) Platform is a proprietary, patented drug compound platform. Hoth Therapeutics Inc. is...

See More

Key Turning Points

2nd Resistance Point 5.34
1st Resistance Point 5.25
Last Price 5.15
1st Support Level 5.03
2nd Support Level 4.90

See More

52-Week High 13.88
Fibonacci 61.8% 9.82
Fibonacci 50% 8.57
Fibonacci 38.2% 7.32
Last Price 5.15
52-Week Low 3.26

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar